Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Placebo for Tecovirimat

Phase 3

NNational Institute of Allergy and Infectious Diseases (NIAID)

Placebo for Tecovirimat is one of 3 therapeutic programs targeting Mpox. It is currently in Phase 3.

1

Indications

1

Total Trials

0

Active Trials

2

Competitors

Pipeline

Status by Indication[2][1]

Indication

MpoxTerminated

MpoxPhase 3

Terminated

Competition

Competitive Landscape

3 competitors in Mpox

#DrugCompanyPhaseTrials

Tpoxx

SSIGA Technologies

Placebo for Tecovirimat

NNational Institute of Allergy and Infectious Diseases (NIAID)

Bnt166a

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mpox1 trial

A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Virus Disease

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT05534984·719 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo for Tecovirimat. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo for Tecovirimat. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Related News